Latest news and press releases about Alaunos Therapeutics, Inc. (TCRT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Price
| Price | $1.28 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADXN · AIM · CYCN · IBO · KTTA · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of TCRT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks